CAMP4 Therapeutics Corporation (NASDAQ: CAMP) is a Healthcare company (Biotechnology) with a market capitalization of $251M. The Maz Rating grades it against the other companies in its sector.
CAMP4 Therapeutics Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $4.00, CAMP4 Therapeutics Corporation trades at 47.2x sales and 2.9x book value. Over the last twelve months it generated about $5M of revenue and a net loss of $129M. It runs a gross margin of 80.4%, an operating margin of -1001.1% and a net margin of -2276.3%. It shows return on equity of -261.8%, return on invested capital of -46.0% and a free cash flow yield of -10.5%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 6.42. Over the past 52 weeks the share price ranged from $2.90 to $7.75, with a beta of 0.21.
CAMP4 Therapeutics Corporation does not currently pay a dividend.
24 Wall Street analyst ratings cover the stock: 16 Buy, 7 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.